Inhibition of c-Jun N-terminal kinase rescues influenza epitope-specific human cytolytic T lymphocytes from activation-induced cell death

J Leukoc Biol. 2007 Feb;81(2):539-47. doi: 10.1189/jlb.0706479. Epub 2006 Oct 24.

Abstract

Cytolytic T lymphocytes (CTL) play an important role in defense against viral infections. Following clonal expansion and effector functions, a vast majority of the antigen-specific CTL undergoes programmed cell death to maintain homeostasis. We have shown earlier that melanoma epitope-specific CTL are quite sensitive to activation-induced cell death (AICD) even on the secondary encounter of the antigen. Excessive sensitivity of viral antigen-specific CTL to AICD, however, would be counterproductive. It might be argued that although CTL for a "self" epitope might be more prone to AICD for maintaining self-tolerance, viral antigen-specific CTL are likely to be less sensitive to AICD. We show here that influenza matrix protein-derived MP(58-66) epitope-specific CTL, activated in vitro and bearing a memory phenotype, are just as sensitive to AICD. The AICD in these CTL is not blocked by the pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp (OMe)-fluoromethylketone or by soluble Ig-Fc chimeras of the death receptors [Fas, TNF receptor (TNF-R), TRAIL-RI, TRAIL-RII]. However, the MP(58-66)-specific CTL can be rescued from AICD by the c-jun-N-terminal kinase (JNK) inhibitor SP600125. These results have implications for immunotherapeutic intervention in rescuing viral epitope-specific CTL from AICD.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Anthracenes / pharmacology*
  • Apoptosis / drug effects
  • Biomarkers / analysis
  • Cell Death / drug effects
  • Cell Death / immunology
  • Cells, Cultured
  • Coculture Techniques
  • Epitopes, T-Lymphocyte / drug effects
  • Epitopes, T-Lymphocyte / immunology*
  • Humans
  • Influenza A virus / immunology
  • JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors*
  • Phenotype
  • Protein Kinase Inhibitors / pharmacology*
  • Sensitivity and Specificity
  • Structure-Activity Relationship
  • T-Lymphocytes, Cytotoxic / drug effects
  • T-Lymphocytes, Cytotoxic / immunology*
  • Viral Matrix Proteins / immunology*

Substances

  • Anthracenes
  • Biomarkers
  • Epitopes, T-Lymphocyte
  • Protein Kinase Inhibitors
  • Viral Matrix Proteins
  • pyrazolanthrone
  • JNK Mitogen-Activated Protein Kinases